NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Mankind Pharma Subsidiary BSV Subjected to 6-Day GST Search and Inspection
The GST Department, Mumbai, conducted a search and inspection operation at Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary of Mankind Pharma. The operation took place over six days, from February 3 to February 8, 2026, under Section 67 of the Maharashtra GST Act. The inspection focused on tax payments, input tax credit claims, reconciliation, and refunds. Mankind Pharma has officially stated that the search has resulted in no material impact on the subsidiary's financials or operations.
முக்கிய அம்சங்கள்
Search conducted by Assistant Commissioner of State Tax (Investigation – B), MumbaiOperation lasted 6 days from February 3 to February 8, 2026Focus areas included GST tax payments, input tax credit (ITC) reconciliation, and refundsManagement confirms no material impact on BSV's financial or operational activitiesBSV is a wholly owned unlisted subsidiary of Mankind Pharma Limited
👀 கவனிக்க வேண்டியவை
Investors should monitor for any subsequent tax demand notices or penalties that may arise from this inspection. While the company claims no material impact, any future liability could affect the subsidiary's valuation.
Mankind Pharma Q3 FY26 Revenue Up 11.5% to ₹3,567 Cr; Adjusted EBITDA Margin at 25.9%
Mankind Pharma reported a steady Q3 FY26 with revenue growing 11.5% YoY to INR 3,567 crores, driven by an 11.1% increase in domestic sales and 14% growth in exports. The company's adjusted EBITDA margin stood at 25.9%, while the chronic segment's contribution rose to 36.7% of total sales. Integration of the BSV acquisition showed positive results with double-digit growth, and the company successfully reduced its net debt to INR 4,294 crores. Management highlighted a recovery in volume growth and significant outperformance in cardio and anti-diabetic therapies compared to the market.
முக்கிய அம்சங்கள்
Q3 FY26 revenue increased 11.5% YoY to ₹3,567 crores with an adjusted EBITDA margin of 25.9%.Chronic therapy contribution rose to 36.7%, with cardio and anti-diabetes growing at 16.7% and 14.4% respectively.Export revenue for 9M FY26 surged 51% YoY to ₹1,503 crores, supported by EU GMP certification for the Udaipur facility.Net debt reduced to ₹4,294 crores, bringing the net debt to adjusted EBITDA ratio down to 1.3x.Domestic PCPM improved to ₹7.2 lakhs from ₹6.5 lakhs on a trailing 12-month basis.
👀 கவனிக்க வேண்டியவை
Investors should monitor the continued integration of BSV and the recovery in the acute segment. The stock remains a strong play on the domestic chronic market and expanding export capabilities.
D-Link India Q3 PAT Rises to ₹9.73 Cr; Faces ₹6.11 Cr Customs Demand & Director Resignation
D-Link (India) reported a steady performance for Q3 FY26, with standalone revenue growing 12.7% year-on-year to ₹375.15 crore. Net profit for the quarter saw a marginal increase to ₹9.73 crore, up from ₹9.44 crore in the previous year's corresponding quarter. The company's bottom line was impacted by a one-time provision of ₹1.92 crore related to the implementation of New Labour Codes. Furthermore, the company is contesting a ₹6.11 crore customs demand regarding royalty payments, while Independent Director Ching Chun Yang has resigned effective February 5, 2026.
முக்கிய அம்சங்கள்
Standalone Revenue from operations grew 12.7% YoY to ₹375.15 crore in Q3 FY26.Net Profit (PAT) for the quarter stood at ₹9.73 crore compared to ₹9.44 crore in Q3 FY25.Recognized ₹1.92 crore in incremental employee benefit obligations due to the New Labour Codes effective Nov 2025.Received a customs demand order of ₹6.11 crore (including penalties) related to royalty payments on third-party imports.Independent Director Ms. Ching Chun Yang resigned from the Board and all committees effective February 5, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the legal proceedings regarding the ₹6.11 crore customs demand and the potential impact of higher employee costs under the New Labour Codes. While revenue growth is stable, the marginal profit growth suggests pressure on margins that warrants a cautious outlook.
D-Link India Q3 Revenue Rises 12.7% to ₹375 Cr; Independent Director Resigns
D-Link (India) Limited reported a steady Q3 FY26 with revenue from operations growing to ₹375.15 crore from ₹332.85 crore YoY. The company's Profit Before Tax remained stable at ₹12.99 crore despite a one-time charge of ₹1.92 crore related to the implementation of New Labour Codes. A significant regulatory update involves a customs demand of ₹6.11 crore regarding royalty payments, which the company is currently evaluating for appeal. Additionally, Independent Director Ms. Ching Chun Yang resigned from the board effective February 5, 2026.
முக்கிய அம்சங்கள்
Revenue from operations increased 12.7% YoY to ₹375.15 crore for the quarter ended December 31, 2025.Profit Before Tax stood at ₹12.99 crore, showing marginal growth over the ₹12.68 crore reported in Q3 FY25.Recognized incremental employee benefit obligations of ₹1.92 crore due to the New Labour Codes effective November 2025.Received a customs demand order of ₹6.11 crore (including penalties) related to royalty payments to the parent company.Independent Director Ms. Ching Chun Yang resigned from the board and all committees effective February 5, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the customs demand appeal and the company's ability to protect margins against rising regulatory and labor costs. The steady revenue growth suggests resilience in the networking products segment.
India Ratings Reaffirms Bank of India’s Infra and Tier 2 Bonds at ‘IND AA+/Stable’
India Ratings has reaffirmed the 'IND AA+/Stable' rating for Bank of India's Infrastructure bonds (₹150 billion) and Tier 2 bonds (₹25 billion). The bank's asset quality has shown significant improvement, with Gross NPA dropping to 2.26% and Net NPA to 0.6% as of 3QFY26. While capital adequacy remains strong at 17.09%, the bank faces pressure on its deposit profile, with the CASA ratio declining to 32.6%. The rating reflects the bank's systemic importance and the high probability of government support given the 73.38% state ownership.
முக்கிய அம்சங்கள்
Reaffirmed 'IND AA+/Stable' rating for ₹150 billion Infrastructure and ₹25 billion Tier 2 bondsGross NPA improved to 2.26% in 3QFY26 from 3.27% in FY25; Net NPA stands at a low 0.6%Capital Adequacy Ratio (CAR) remains healthy at 17.09% with a CET-1 ratio of 13.76%Return on Assets (RoA) improved to 0.96% in 3QFY26, up from 0.70% in FY24CASA ratio declined to 32.6%, highlighting ongoing challenges in low-cost deposit mobilization
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the improving asset quality and stable credit rating which supports the bank's growth outlook. Monitor the bank's deposit growth and CASA ratio as they remain key areas of competitive pressure.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
D-Link India Q3 FY26 Revenue at ₹375.15 Cr; PBT Grows 33.5% YoY to ₹13 Cr
D-Link (India) Limited reported a steady year-on-year performance for the quarter ended December 31, 2025, with revenue from operations growing 12.7% to ₹375.15 crore. Profit Before Tax (PBT) saw a robust increase of 33.5% YoY, reaching ₹13 crore, although revenue dipped slightly on a sequential basis. The company is currently managing a regulatory challenge following a ₹6.11 crore customs demand related to royalty payments. Additionally, the firm has accounted for a ₹1.92 crore provision due to the implementation of New Labour Codes effective November 2025.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹375.15 crore in Q3 FY26 from ₹332.85 crore in Q3 FY25.Profit Before Tax (PBT) rose to ₹13.00 crore compared to ₹9.73 crore in the same quarter last year.Received a customs demand order of ₹611.49 lakhs regarding royalty payments, which the company is evaluating for appeal.Recognized incremental employee benefit obligations of ₹192.41 lakhs due to the implementation of New Labour Codes.Independent Director Ms. Ching Chun Yang resigned from the Board and its committees effective February 5, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the customs demand appeal as it represents a potential liability. While YoY profit growth is strong, the sequential stagnation in revenue suggests a need to watch for signs of slowing demand in the networking products segment.
NK Industries Approves Q3 FY26 Standalone and Consolidated Financial Results
NK Industries Limited has approved its unaudited standalone and consolidated financial results for the quarter and nine-month period ended December 31, 2025. The board meeting, held on February 4, 2026, also reviewed and accepted the Limited Review Report provided by the auditors. This announcement is a standard regulatory requirement under SEBI (LODR) Regulations. Investors should now examine the specific financial tables to assess the company's revenue and profit performance for the quarter.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated financial results for the quarter ended December 31, 2025.The Limited Review Report for the nine-month period was formally taken on record.The board meeting commenced at 3:30 P.M. and concluded at 5:00 P.M. on February 4, 2026.Compliance maintained with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed profit and loss statements and balance sheet figures once the full report is available to evaluate the company's growth trajectory. Compare these results with previous quarters to identify any significant changes in operational margins.
Mankind Pharma Q3 FY26 Standalone PAT at ₹449.47 Cr; Revenue at ₹2,632.68 Cr
Mankind Pharma reported a steady performance for Q3 FY26 with standalone revenue from operations at ₹2,632.68 crore, showing a marginal sequential dip from ₹2,636.95 crore in Q2. Standalone Profit After Tax (PAT) stood at ₹449.47 crore, slightly lower than the ₹462.27 crore reported in the previous quarter, partly due to an exceptional item of ₹83.42 crore. The financial results have been restated to account for the acquisition of Bharat Serums and Vaccines Limited (BSV) and other business combinations. Overall, the company maintains a strong balance sheet with a total comprehensive income of ₹452.53 crore for the quarter.
முக்கிய அம்சங்கள்
Standalone Revenue from operations stood at ₹2,632.68 crore for the quarter ended December 31, 2025.Standalone Profit After Tax (PAT) reached ₹449.47 crore, impacted by an exceptional charge of ₹83.42 crore.Basic Earnings Per Share (EPS) for the quarter was reported at ₹10.89.Financials were restated to reflect the impact of the Bharat Serums and Vaccines Limited (BSV) acquisition.Total expenses for the quarter were managed at ₹2,100.49 crore compared to ₹2,189.09 crore in the preceding quarter.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration progress of the BSV acquisition and the reasons behind the exceptional item. While sequential growth was flat, the company's domestic market leadership remains a key long-term positive.
Mankind Pharma Q3 FY26: Revenue up 11.5% to ₹3,567 Cr; Chronic share rises to 39.3%
Mankind Pharma reported a steady 11.5% YoY revenue growth in Q3 FY26, reaching ₹3,567 crore, primarily driven by domestic pharma and the consolidation of BSV. The company's chronic segment showed strong momentum, with its share increasing by 200bps to 39.3%, led by high growth in Cardiac (16.7%) and Anti-Diabetes (14.4%) therapies. While reported EBITDA margins were 22.9%, adjusted margins stood at 25.9% after accounting for one-time labor code impacts. The Consumer Healthcare segment regained momentum with 5.2% growth, and the export business grew by 14.1% YoY.
முக்கிய அம்சங்கள்
Revenue from operations grew 11.5% YoY to ₹3,567 crore, with domestic business contributing ₹3,046 crore.Chronic segment share increased to 39.3% from 37.3% YoY, significantly outperforming the Indian Pharma Market (IPM) in key therapies.Adjusted EBITDA margin stood at 25.9%, while PAT grew 9.5% YoY to ₹414 crore.Export business witnessed 14.1% YoY growth, reaching ₹521 crore, aided by BSV international business.Net debt reduced to ₹4,294 crore as of Dec 31, 2025, from ₹6,739 crore in Dec 2024, showing strong cash flow utilization.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition toward a higher-margin chronic portfolio and the smooth integration of the BSV acquisition. The stock remains a strong play on the domestic pharmaceutical market with improving capital efficiency.
Bank of India Q3 FY26 Net Profit Rises 7% YoY to ₹2,705 Cr; NIM Improves to 2.57%
Bank of India reported a steady performance for Q3 FY26, with net profit growing 7% YoY to ₹2,705 crore and operating profit rising 13% to ₹4,193 crore. Asset quality showed significant improvement as Gross NPA fell by 143 bps YoY to 2.26%, while Net NPA reached a low of 0.60%. The bank successfully improved its Global NIM by 16 bps sequentially to 2.57% through portfolio churning and shedding low-yield assets. With a strong corporate pipeline of ₹65,000 crore and robust RAM growth of 18.05%, the management maintains a positive outlook for FY27.
முக்கிய அம்சங்கள்
Net Profit increased by 7% YoY to ₹2,705 crore, while Net Interest Income grew 6% to ₹6,461 crore.Asset quality improved drastically with Gross NPA at 2.26% and Net NPA at 0.60%, supported by a high PCR of 93.60%.Domestic advances grew 15.16% YoY, led by an 18.05% surge in RAM (Retail, Agri, MSME) segments.Global NIM expanded by 16 bps sequentially to 2.57% due to strategic churning of low-yielding assets.Capital Adequacy Ratio (CRAR) remains strong at 17.09% as of December 2025 compared to 16.00% YoY.
👀 கவனிக்க வேண்டியவை
Investors should focus on the bank's improving margins and robust asset quality metrics. The strong corporate credit pipeline and focus on high-yield RAM segments provide a positive outlook for earnings growth in FY27.
Bank of India Q3 Net Profit Up 7.5% YoY to ₹2,705 Cr; Gross NPA Drops to 2.26%
Bank of India reported a standalone net profit of ₹2,704.67 crore for the quarter ended December 2025, a 7.5% increase from ₹2,516.69 crore in the previous year. The bank's asset quality improved remarkably, with Gross NPA declining to 2.26% from 3.69% YoY and Net NPA falling to 0.60%. Total income for the quarter stood at ₹21,205.95 crore, supported by a 13.2% growth in operating profit. The Capital Adequacy Ratio remains robust at 17.09%, up from 16.00% in the year-ago period.
முக்கிய அம்சங்கள்
Standalone Net Profit rose 7.5% YoY to ₹2,704.67 crore from ₹2,516.69 croreGross NPA ratio saw a sharp decline to 2.26% from 3.69% YoY and 2.54% QoQNet NPA ratio improved to 0.60% from 0.85% in the same quarter last yearOperating Profit increased by 13.2% YoY to ₹4,192.79 croreCapital Adequacy Ratio (Basel III) improved to 17.09% from 16.00% YoY
👀 கவனிக்க வேண்டியவை
The significant improvement in asset quality and healthy capital position make the stock attractive for long-term investors. Monitor the credit growth trajectory in the wholesale and retail segments to ensure sustained profitability.
Bank of India Q3FY26 Net Profit Rises 7.5% YoY to ₹2,705 Cr; Asset Quality Improves Sharply
Bank of India reported a steady Q3FY26 with net profit growing 7.47% YoY to ₹2,705 crores, supported by a 13.24% increase in operating profit. Asset quality showed significant improvement as Gross NPA fell to 2.26% from 3.69% YoY, and Net NPA reached 0.60%. While the domestic Net Interest Margin (NIM) at 2.80% is lower than last year's 2.98%, it showed a healthy sequential recovery from 2.66% in Q2FY26. The bank's global business crossed the ₹16 lakh crore milestone, driven by robust 15.16% growth in domestic advances.
முக்கிய அம்சங்கள்
Net Profit for Q3FY26 increased 7.47% YoY to ₹2,705 crores; 9M-FY26 profit rose 14% to ₹7,511 crores.Gross NPA ratio improved significantly by 143 bps YoY to 2.26%, while Net NPA improved to 0.60%.Global Advances grew 13.63% YoY to ₹7.40 lakh crores, with Retail advances leading at 20.64% growth.Domestic NIM recovered to 2.80% from 2.66% in the previous quarter, though down from 2.98% YoY.Capital Adequacy Ratio (CAR) remains strong at 17.09% with a high Provision Coverage Ratio of 93.60%.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the bank's superior asset quality and the sequential recovery in margins. The strong capital position and double-digit growth in RAM advances make it a stable pick in the PSU banking sector.
Mankind Pharma has announced the withdrawal of its (ICRA) A1+ credit rating for Commercial Paper worth ₹1,500 crore at its own request. Despite this withdrawal, the company's core credit profile remains strong with an outstanding (ICRA) AA+/Stable rating for its ₹5,000 crore Non-Convertible Debentures. Additionally, fund-based limits totaling ₹1,250 crore retain their high-grade (ICRA) AA+ (Stable) and (ICRA) A1+ ratings. This update confirms that the company's creditworthiness and ability to service debt remain robust.
முக்கிய அம்சங்கள்
ICRA withdrew the (ICRA) A1+ rating for ₹1,500 crore Commercial Paper at the company's request.Outstanding rating for ₹5,000 crore Non-Convertible Debentures remains stable at (ICRA) AA+.Long-term and short-term fund-based limits of ₹1,250 crore maintain (ICRA) AA+ (Stable) and (ICRA) A1+ ratings.The withdrawal of the CP rating is a procedural action and does not indicate a downgrade in credit quality.
👀 கவனிக்க வேண்டியவை
Investors should treat this as a routine administrative update as the company's primary credit ratings remain high and stable. No immediate action is required as the fundamental debt-servicing capability remains unchanged.
JNK India Seeks Approval for Related Party Transactions Worth Over ‑192 Crore
JNK India Limited has issued a postal ballot notice to seek shareholder approval for two significant Related Party Transactions (RPTs) for FY 2025-26. The first proposal involves transactions up to ‑70 crore with its subsidiary, JNK Chemdist Technologies Private Limited (JCTPL), covering loans, investments, and services. The second proposal seeks approval for transactions up to ‑122.30 crore between JCTPL and Chemdist Process Solutions Private Limited for the purchase of goods and assets. Both sets of transactions are reported to be at arm's length and within the ordinary course of business.
முக்கிய அம்சங்கள்
Proposed ‑70 crore transaction limit with subsidiary JNK Chemdist Technologies for FY 2025-26Proposed ‑122.30 crore transaction limit between subsidiary JCTPL and Chemdist Process SolutionsTransactions include inter-corporate loans, investments, and procurement of goods/assetsRemote e-voting period is set from January 9, 2026, to February 7, 2026Final voting results to be declared on or before February 10, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to ensure corporate governance standards are maintained and review the impact of these intra-group transactions on the company's consolidated cash flows.
Bank of India Q3 FY26 Update: Global Business Grows 12.5% YoY to ₹16.27 Lakh Crore
Bank of India reported a robust provisional performance for Q3 FY26, with its global business reaching ₹16.27 lakh crore, a 12.50% YoY increase. Global gross advances grew by 13.55% YoY to ₹7.39 lakh crore, while global deposits rose 11.64% to ₹8.87 lakh crore. A key highlight is the domestic RAM (Retail, Agri, MSME) segment, which surged 17.69% YoY to ₹3.67 lakh crore. Domestic credit growth at 15.07% continues to outpace domestic deposit growth of 12.80%, indicating strong credit demand.
முக்கிய அம்சங்கள்
Global Business reached ₹16,27,098 crore, registering a 12.50% YoY growth.Domestic Gross Advances grew by 15.07% YoY to ₹6,28,617 crore.Domestic RAM (Retail, Agri, MSME) advances showed strong momentum with 17.69% YoY growth.Global Deposits increased to ₹8,87,287 crore, up 11.64% from ₹7,94,788 crore in the previous year.Domestic Deposits grew by 12.80% YoY, reaching ₹7,65,500 crore.
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in advances, particularly in the high-margin RAM segment, is a positive indicator for future earnings. Investors should hold the stock and monitor the full quarterly results for impact on Net Interest Margins (NIMs) and asset quality.
Bank of India Allots Rs 10,000 Crore Long Term Infrastructure Bonds at 7.23% Coupon
Bank of India has successfully completed the allotment of Series IV Long Term Infrastructure Bonds totaling Rs 10,000 crore. The issue, conducted on a private placement basis, included a base size of Rs 5,000 crore and a fully exercised green shoe option of Rs 5,000 crore. These unsecured, non-convertible bonds carry a coupon rate of 7.23% per annum and were allotted to 11 institutional investors. This capital raise is intended to strengthen the bank's long-term resources for financing infrastructure projects.
முக்கிய அம்சங்கள்
Total allotment of Rs 10,000 crore through 10,00,000 bonds with a face value of Rs 1 lakh each.Coupon rate fixed at 7.23% per annum, reflecting competitive borrowing costs for the PSU bank.Successfully exercised the full green shoe option of Rs 5,000 crore over the base issue.The allotment was finalized on December 26, 2025, involving 11 allottees.
👀 கவனிக்க வேண்டியவை
The successful fundraise at a competitive rate enhances the bank's capacity for long-term credit growth in the infrastructure sector. Investors should remain positive as this provides stable long-term funding without equity dilution.
Bank of India Raises Rs 10,000 Crore via Infrastructure Bonds at 7.23% Coupon
Bank of India has successfully raised Rs 10,000 crore through the issuance of Long Term Infrastructure Bonds (Series IV) on a private placement basis. The issue saw strong investor interest, being oversubscribed by 3.06 times against the base size of Rs 5,000 crore, with total bids reaching Rs 15,305 crore. The bank accepted the full Rs 10,000 crore (including the green shoe option) at a competitive coupon rate of 7.23% per annum. This capital raise will support the bank's long-term lending capabilities in the infrastructure sector.
முக்கிய அம்சங்கள்
Raised Rs 10,000 crore through Long Term Infrastructure Bonds Series IVIssue oversubscribed 3.06x against base size with bids totaling Rs 15,305 croreFinal coupon rate fixed at 7.23% per annum on a private placement basisAccepted 37 bids out of 83 received on the NSE Electronic Bidding PlatformDeemed date of allotment is scheduled for December 26, 2025
👀 கவனிக்க வேண்டியவை
The strong oversubscription and competitive pricing reflect high institutional confidence in the bank's creditworthiness. Investors should monitor how this low-cost long-term capital improves the bank's margins and infrastructure lending book.
CRISIL Assigns 'AA+/Stable' to Bank of India's ₹10,000 Cr Infra Bonds; Reaffirms Existing Ratings
CRISIL Ratings has assigned a 'CRISIL AA+/Stable' rating to Bank of India's new ₹10,000 crore infrastructure bonds and reaffirmed ratings for its existing Tier I and Tier II bonds. The bank's asset quality has shown marked improvement, with Gross NPA declining to 2.5% as of September 2025 from 3.3% in March 2025. Financial stability is supported by a healthy Capital Adequacy Ratio of 17.2% and a majority government stake of 73.38%. Profitability has also stabilized with a Return on Assets (RoA) of 0.9% for the first half of fiscal 2026.
முக்கிய அம்சங்கள்
Assigned 'CRISIL AA+/Stable' rating to new ₹10,000 crore Infrastructure Bonds.Gross NPA improved significantly to 2.5% in Sept 2025 from 4.98% in March 2024.Capital Adequacy Ratio (CRAR) remains robust at 17.2% as of September 30, 2025.Domestic CASA deposits stood at 39.4%, supporting a comfortable resource profile.Net profit for H1 FY2026 reached ₹4,807 crore with an annualized RoA of 0.9%.
👀 கவனிக்க வேண்டியவை
Investors can take confidence in the bank's improving asset quality and strong government backing. The high credit rating for the new infrastructure bonds indicates a stable financial outlook and efficient capital management.
JNK India CFO Pravin Sathe Resigns Effective December 16, 2025
JNK India Limited has announced the resignation of Mr. Pravin Sathe from the position of Chief Financial Officer, effective from the close of business hours on December 16, 2025. Mr. Sathe is stepping down to pursue other professional opportunities outside the organization. Consequently, he will also cease to be a Key Managerial Personnel (KMP) and Senior Management Personnel (SMP) of the company. The company has not yet named a successor for the CFO role in this official communication.
முக்கிய அம்சங்கள்
Mr. Pravin Sathe resigned as CFO, KMP, and SMP effective December 16, 2025.The resignation is attributed to the pursuit of other professional opportunities.The cessation is effective from the close of business hours on the date of the announcement.The filing complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure a smooth leadership transition. While the resignation appears routine, the timely replacement of a KMP is essential for maintaining financial oversight.
Bank of India to Raise Rs 2,500 Crore via Basel III Compliant Tier II Bonds
Bank of India has announced its plan to raise Rs 2,500 crore through the issuance of Basel III compliant Tier II bonds. This capital raising exercise is designed to strengthen the bank's Tier II capital base and improve its overall Capital Adequacy Ratio (CAR). By opting for Tier II bonds, the bank can augment its regulatory capital without diluting existing shareholder equity. This move supports the bank's long-term credit growth objectives and ensures compliance with stringent RBI capital norms.
முக்கிய அம்சங்கள்
Proposed issuance of Basel III compliant Tier II bonds worth Rs 2,500 crore.The fundraise aims to strengthen the bank's regulatory capital base.The move supports future credit expansion and improves the Capital Adequacy Ratio.Tier II bonds provide a cost-effective way to raise capital without equity dilution.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final coupon rate and credit rating of the bonds as indicators of market confidence in the bank's financial health.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
